Assessment of Any Potential Retinal Effects of Tafenoquine (TQ)

NCT02658435 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

486

Enrollment

INDUSTRY

Sponsor class

Conditions

Malaria, Vivax

Interventions

DRUG: Tafenoquine 150 mg
DRUG: Matched placebo 150mg

Sponsor

GlaxoSmithKline

Collaborators

[object Object]